The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance

Abstract

The type 2 DNA topoisomerases (Top2) are conserved enzymes and biomarkers for cell proliferation. The catalytic activities of the human isoform Top2α are essential for the regulation of DNA topology during DNA replication, transcription, and chromosome segregation. Top2α is a prominent target for anti-cancer drugs and is highly regulated by post-translational modifications (PTM). Despite an increasing number of proteomic studies, the extent of PTM in cancer cells and its importance in drug response remains largely uncharacterized. In this review, we highlight the different modifications affecting the human Top2α in healthy and cancer cells, taking advantage of the structure-function information accumulated in the past decades. We also overview the regulation of Top2α by PTM, the level of PTM in cancer cells, and the resistance to therapeutic compounds targeting the Top2 enzyme. Altogether, this review underlines the importance of future studies addressing more systematically the interplay between PTM and Top2 drug resistance.

Keywords

DNA topoisomerase / drug resistance / post-translational modifications / etoposide

References

[1] Ali Y.Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy..Tumor Biol2016;37:47-55

[2] Mondal N.DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates..Nature2001;413:435-8

[3] Akimitsu N,Hirai H,Hamamoto H.Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase II alpha..Genes Cells2003;8:393-402

[4] Collins I,Levens D.Transcriptional consequences of topoisomerase inhibition..Mol Cell Biol2001;21:8437-51 PMCID:PMC100007

[5] Champoux JJ.DNA topoisomerases: structure, function, and mechanism..Annu Rev Biochem2001;70:369-413

[6] Clarke DJ.Non-catalytic roles of the topoisomerase II C-terminal domain..Int J Mol Sci2017;18: PMCID:PMC5713405

[7] Nitiss JL.Targeting DNA topoisomerase II in cancer chemotherapy..Nat Rev Cancer2009;9:338-50 PMCID:PMC2748742

[8] Roca J,Berger JM,Wang JC.Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase-Ii by trapping the enzyme in the form of a closed protein clamp..Proc Natl Acad Sci U S A1994;91:1781-5 PMCID:PMC43247

[9] Wu CC,Farh L,Lin TS.Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide..Science2011;333:459-62

[10] Vassetzky YS,Gasser SM.DNA topoisomerase II mutations and resistance to anti-tumor drugs..Bioessays1995;17:767-74

[11] Cicenas J,Bairoch A.Kinases and cancer..Cancers (Basel)2018;10: PMCID:PMC5876638

[12] Han ZJ,Gu BH,Chen H.The post-translational modification, SUMOylation, and cancer (review)..Int J Oncol2018;52:1081-94 PMCID:PMC5843405

[13] Saijo M,Hanaoka F.Purification and characterization of type II DNA topoisomerase from mouse Fm3a cells: phosphorylation of topoisomerase-Ii and modification of its activity..Biochemistry1990;29:583-90

[14] Mann M.Proteomic analysis of post-translational modifications..Nat Biotechnol2003;21:255-61

[15] Chen T,Ji P,Zhang W.Topoisomerase IIalpha in chromosome instability and personalized cancer therapy..Oncogene2015;34:4019-31 PMCID:PMC4404185

[16] Bedez C,Batisse C,Stote RH.Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain..Sci Rep2018;8:9272 PMCID:PMC6006247

[17] Wells NJ,Guano F,Hickson ID.Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C..J Biol Chem1995;270:28357-63

[18] Grozav AG,Grabowski DR,Kinter M.Casein kinase I delta/epsilon isoforms phosphorylate serine 1106 in the catalytic domain of human topoisomerase II alpha..Cancer Res2006;47:

[19] Shapiro PS,Tolwinski NS,Froelich-Ammon SJ.Extracellular signal-regulated kinase activates topoisomerase II alpha through a mechanism independent of phosphorylation..Mol Cell Biol1999;19:3551-60 PMCID:PMC84147

[20] Adachi N,Kato S,Koyama H.Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain..Nucleic Acids Res1997;25:3135-42 PMCID:PMC146861

[21] Ishida R,Koujin T,Nozaki N.Mitotic specific phosphorylation of serine-1212 in human DNA topoisomerase II alpha..Cell Struct Funct2001;26:215-26

[22] Devore RF,Osheroff N.Phosphorylation of topoisomerase II by casein kinase II and protein kinase c: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4’-(9-Acridinylamino) methane-sulfon-m-anisidide..Cancer Res1992;52:2156-61

[23] Plo I,Kohlhagen G,Pommier Y.Overexpression of the atypical protein kinase C reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells..J Biol Chem2002;277:31407-15

[24] Chikamori K,Kinter M,Yadav S.Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity..J Biol Chem2003;278:12696-702

[25] Shiozaki K.Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase-II..J Cell Biol1992;119:1023-36 PMCID:PMC2289710

[26] Luo KT,Chen JJ.Topoisomerase IIalpha controls the decatenation checkpoint..Nat Cell Biol2009;11:204-10 PMCID:PMC2712943

[27] Wells NJ,Fry AM,Hickson ID.Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase II in vitro..J Biol Chem1994;269:29746-51

[28] Li H,Liu X.Plk1-dependent phosphorylation regulates functions of DNA topoisomerase II alpha in cell cycle progression..J Biol Chem2008;283:6209-21

[29] Qi XM,Lepp A,Basir Z.Phosphorylation and stabilization of topoisomerase II alpha protein by p38 gamma mitogen-activated protein kinase sensitize breast cancer cells to its poisons..J Biol Chem2011;286:35883-90 PMCID:PMC3195563

[30] Lane AB,Clarke DJ.A novel chromatin tether domain controls topoisomerase II alpha dynamics and mitotic chromosome formation..J Cell Biol2013;203:471-86 PMCID:PMC3824022

[31] Corbett AH,Osheroff N.Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of atp hydrolysis: evidence for a common mechanism of regulation by phosphorylation..Biochemistry1993;32:2090-7

[32] Corbett AH,Osheroff N.Effect of casein kinase-II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis..J Biol Chem1992;267:20513-8

[33] Takano H,Ono M,Kuwano M.Increased phosphorylation of DNA topoisomerase-II in etoposide-resistant mutants of human cancer KB cells..Cancer Res1991;51:3951-7

[34] Nakazawa N,Ebe M.Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast..J Biol Chem2019;294:3772-82 PMCID:PMC6416453

[35] Matsumoto Y,Fojo T.Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype..Cancer Res1997;57:5086-92

[36] Ritke MK,Fattman C,Yalowich JC.Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells..Mol Pharmacol1994;46:58-66

[37] Ganapathi R,Kamath N,Grabowski D.Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides..Mol Pharmacol1996;50:243-48

[38] Choudhary C,Nishida Y,Mann M.The growing landscape of lysine acetylation links metabolism and cell signalling..Nat Rev Mol Cell Biol2014;15:536-50

[39] Mertins P,Patel J,Clauser KR.Integrated proteomic analysis of post-translational modifications by serial enrichment..Nat Methods2013;10:634-7 PMCID:PMC3943163

[40] Hornbeck PV,Murray B,Latham V.PhosphoSitePlus, 2014: mutations, PTMs and recalibrations..Nucleic Acids Res2015;43:D512-20 PMCID:PMC4383998

[41] Wu Q,Zhu J,Peng XJ.Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line..Sci Rep2015;5:9520 PMCID:PMC4379480

[42] Udeshi ND,Mertins P,Mani DR.Refined preparation and use of anti-diglycine remnant (K-epsilon-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments..Mol Cell Proteomics2013;12:825-31 PMCID:PMC3591673

[43] Kim W,Huttlin EL,Li J.Systematic and quantitative assessment of the ubiquitin-modified proteome..Mol Cell2011;44:325-40 PMCID:PMC3200427

[44] Povlsen LK,Wagner SA,Sylvestersen KB.Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass..Nat Cell Biol2012;14:1089-98

[45] Wagner SA,Weinert BT,Cox J.A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles..Mol Cell Proteomics2011;10:M111.013284 PMCID:PMC3205876

[46] Akimov V,Hansen SVF,Pedersen AK.UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites..Nat Struct Mol Biol2018;25:631-40

[47] Hendriks IA,Yang B,Mann M.Uncovering global SUMOylation signaling networks in a site-specific manner..Nat Struct Molr Biol2014;21:927-36 PMCID:PMC4259010

[48] Tsai SC,Yang WM,Sullivan D.Histone deacetylase interacts directly with DNA topoisomerase II..Nat Genet2000;26:349-53

[49] Johnson CA,Austin CA.Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis..J Biol Chem2001;276:4539-42

[50] Chen MC,Chuang HC,Teng CM.Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II alpha degradation in hepatocellular carcinoma cells..Hepatology2011;53:148-59 PMCID:PMC3058595

[51] Gilberto S.Dynamic ubiquitin signaling in cell cycle regulation..J Cell Biol2017;216:2259-71 PMCID:PMC5551716

[52] Eguren M,Garcia F,Fujimitsu K.A synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens..Cell Rep2014;6:670-83

[53] Guturi KKN,Bohgaki T,Ng D.RNF168 and USP10 regulate topoisomerase II alpha function via opposing effects on its ubiquitylation..Nat Commun2016;7:12638 PMCID:PMC5007378

[54] Kang X,Du X,Liu Y.PTEN stabilizes TOP2A and regulates the DNA decatenation..Sci Rep2015;5:17873 PMCID:PMC4674714

[55] Fielding AB,Darling S,Sacco JJ.The deubiquitylase USP15 regulates topoisomerase II alpha to maintain genome integrity..Oncogene2018;37:2326-42 PMCID:PMC5916918

[56] Senturk JC,Manfredi JJ.Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53..Oncogene2017;36:6085-96 PMCID:PMC5987529

[57] Ogiso Y,Lei SH,Tsuruo T.Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs..Cancer Res2000;60:2429-34

[58] Alchanati I,Cohen G,Barr HM.The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2 alpha cleavage complex - a potentially new drug target..PloS One2009;4:e8104 PMCID:PMC2779455

[59] Sun Y, Miller Jenkins LM, Su YP, Nitiss KC, Nitiss JL, et al. A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZI drives proteasomal degradation of topoisomerase DNA-protein crosslinks. Bio Rxiv 2019. Available from: https://www.biorxiv.org/content/10.1101/707661v1 [Last accessed on 20 Feb 2020]

[60] Hay RT.SUMO: a history of modification..Mol Cell2005;18:1-12

[61] Schellenberg MJ,Herrero-Ruiz A,Williams JG.ZATT (ZNF451)-mediated resolution of topoisomerase 2 DNA-protein cross-links..Science2017;357:1412-6 PMCID:PMC5623066

[62] Dawlaty MM,Jeganathan KB,Sustmann C.Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase II alpha..Cell2008;133:103-15 PMCID:PMC2693193

[63] Ryu H,Kirkpatrick D,Azuma Y.PIASy-dependent SUMOylation regulates DNA topoisomerase II alpha activity..J Cell Biol2010;191:783-94 PMCID:PMC2983052

[64] Antoniou-Kourounioti M,Porter ACG.The impact of the C-terminal region on the interaction of topoisomerase II alpha with mitotic chromatin..Int J Mol Sci2019;20: PMCID:PMC6429393

[65] Edgerton H,Keifenheim D,Chacon JM.A noncatalytic function of the topoisomerase II CTD in Aurora B recruitment to inner centromeres during mitosis..J Cell Biol2016;213:651-64 PMCID:PMC4915189

[66] Chen SF,Lin JH,Wang YR.Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate..Nat Commun2018;9:3085 PMCID:PMC6078968

[67] Vanden Broeck A,Ortiz J.Cryo-EM structure of the complete E. coli DNA gyrase nucleoprotein complex..Nat Commun2019;10:4935 PMCID:PMC6821735

[68] Petrella S,Raynal B,Thureau A.Overall structures of mycobacterium tuberculosis DNA gyrase reveal the role of a corynebacteriales GyrB-specific insert in ATPase activity..Structure2019;27:579-89.e5

[69] Wendorff TJ,Heslop P,Berger JM.The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage..J Mol Biol2012;424:109-24 PMCID:PMC3584591

[70] Agostinho M,Ferreira F,Cardoso J.Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity..Cancer Res2008;68:2409-18

[71] Mao Y,Liu LF.SUMO-1 conjugation to human DNA topoisomerase II isozymes..J Biol Chem2000;275:26066-73

[72] Blower TR,Lee ASY,Nitiss JL.A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents..Nucleic Acids Res2019;47:8163-79 PMCID:PMC6735899

[73] Wessel I,Renodon-Corniere A,Nitiss JL.Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the walker A ATP binding site of topoisomerase II alpha..FEBS Lett2002;520:161-6

[74] Renodon-Corniere A,Nitiss JL,Sehested M.Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance..Biochemistry2003;42:9749-54

[75] Jensen LH,Moller M,Sehested M.N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance..FEBS Lett2000;480:201-7

[76] Miller ML,Petersen TN.NetPhosK - Prediction of kinase-specific phosphorylation from sequence and sequence-derived features..Febs J2005;272:111